pDONR223-DDR1 Citations (2)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-DDR1
| Articles |
|---|
Physical and functional interactome atlas of human receptor tyrosine kinases.
Salokas K, Liu X, Ohman T, Chowdhury I, Gawriyski L, Keskitalo S, Varjosalo M.
EMBO Rep. 2022 Apr 5:e54041. doi: 10.15252/embr.202154041.
PubMed
Associated Plasmids |
| Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Nishida-Aoki N, Zhu S, Chan M, Kang Y, Fujita M, Jiang X, McCabe M, Vaz JM, Davidson NE, Ghajar CM, Hansen K, Welm AL, Pillarisetty VG, Gujral TS. Cell Rep Med. 2025 Oct 21;6(10):102357. doi: 10.1016/j.xcrm.2025.102357. Epub 2025 Sep 19. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.